Medroxyprogesterone Acetate News and Research

RSS

Women who initiate hormone therapy closer to menopause tend to have a reduced risk of coronary heart disease

Studies examining the effects of the use of postmenopausal hormone therapy on coronary heart disease (CHD) have yielded mixed results, depending on the type of study conducted. There may be a number of reasons for the differences, including the timing of initiation of hormone therapy, according to background information in the article.

4 Apr 2007

Is there any role for thalidomide as a monotherapy in the management of metastatic renal cell carcinoma?

Thalidomide remains an enigma in the treatment of metastatic renal cell carcinoma (RCC). Initial clinical trials suggested a benefit, but more recently, subsequent randomized trials studying thalidomide in combination with other agents such as interferon have demonstrated no added benefit.

8 Mar 2006

NIH Panel supports use of hormone therapy for treatment of menopausal symptoms

A panel meeting in conjunction with this week's Conference on the Management of Menopause-Related Symptoms, convened by the National Institutes of Health (NIH), has issued a statement supporting the use of postmenopausal hormone therapy (HT) for the management of moderate to severe menopausal symptoms, such as hot flashes, night sweats, and vaginal dryness.

23 Mar 2005

Increased risk of urinary incontinence with hormone therapy

Menopausal hormone therapy (MHT), consisting of oral estrogen plus progestin or estrogen alone, considered in the past as treatment for urinary incontinenc, was until recently, credited with many benefits well beyond the indications for symptomatic relief of hot flashes, night sweats, and vaginal dryness. One of the benefits of MHT was to improve the symptoms of urinary incontinence (UI), and it has often been prescribed to treat UI.

21 Feb 2005

Progestin in hormone therapy could dramatically affect heart attack severity

“One type of hormone therapy limited heart muscle damage to only 5 percent while another resulted in permanent damage to 35 percent of muscle,” said J. Koudy Williams, Ph.D., lead investigator, from Wake Forest Baptist. “If we can learn more about this mechanism we might be able to identify better hormone therapies for postmenopausal women.”

10 Oct 2004

Women who take the hormone therapy estrogen plus progestin have double the risk for venous thrombosis

Mary Cushman, M.D., M.Sc., of the University of Vermont, Colchester, Vt., and colleagues examined the effects of postmenopausal hormone therapy on VT in the presence of other thrombosis risk factors, such as age and obesity.

5 Oct 2004

Popular injectable contraceptive increases risk of STD's

The injectable contraceptive depot-medroxyprogesterone acetate (DMPA) appears to increase a woman’s risk of acquiring the sexually transmitted infections chlamydia and gonorrhea by approximately three fold when compared to women not using a hormonal contraceptive

23 Aug 2004

Findings from WHI memory study may not directly apply to newly menopausal women

The WHIMS article reported that estrogen therapy does not decrease, but may increase, the risk of probable dementia in women age 65 and older using hormones compared to women taking placebo.

23 Jun 2004

Estrogen therapy may increase the risk for dementia

A new study in the Journal of the American Medical Association (JAMA) suggests that estrogen therapy does not decrease, but may increase, the risk for dementia in older, postmenopausal women.

22 Jun 2004